Can a Patient's own blood proteins help rebuild bone lost to gum disease?

NCT ID NCT07805317

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This trial tests whether adding a gel made from a patient's own blood, called albumin platelet-rich fibrin, improves the results of regenerative surgery for severe gum disease. Adults with stage III periodontitis and deep bone defects will receive standard surgery with a bone graft, and half will also get the blood gel placed in the defect. Researchers will measure how much gum attachment and bone fill improve over six to nine months, along with pain, healing, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Albumin platelet-rich fibrin (Alb-PRF), a blood-derived biomaterial, added to regenerative periodontal surgery
What this could lead to
If it works, adding Alb-PRF to gum surgery could improve tissue reattachment and bone fill, potentially slowing tooth loss from severe periodontitis.
What could go wrong
This is a small early trial with 24 participants, so results may not apply broadly. The added biomaterial could also fail to improve outcomes or cause minor side effects like pain or swelling.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 to 65 years. * Diagnosis of Stage III periodontitis according to the 2017 classification of periodontal and peri-implant diseases and conditions. * Completion of nonsurgical periodontal therapy and oral hygiene instruction before surgical treatment. * Presence of at least one interproximal intrabony periodontal defect considered suitable for regenerative periodontal surgery. * Residual probing depth of at least 6 mm and clinical attachment loss of at least 6 mm at the selected site following nonsurgical periodontal therapy. * Radiographic evidence of an intrabony defect component of at least 3 mm at the selected site. * Adequate plaque control and compliance with oral hygiene instructions. * Ability to understand the study procedures, provide written informed consent, and attend all scheduled follow-up visits. Exclusion Criteria: * Current smoking or smoking cessation within the previous 6 months. * Uncontrolled diabetes mellitus, serious cardiovascular disease, autoimmune disease, liver or kidney failure, immunodeficiency, or another systemic condition that may adversely affect periodontal healing or surgical treatment. * Pregnancy or lactation. * Presence of a hematologic disorder, bleeding disorder, anticoagulant therapy, or another condition that may interfere with venous blood collection or periodontal surgery. * Use of antibiotics, systemic corticosteroids, immunosuppressive agents, bisphosphonates, antiresorptive agents, or other medications known to affect periodontal or bone healing within the previous 6 months. * Periodontal surgical treatment at the selected site within the previous 6 months. * Acute periodontal or endodontic infection at the selected site. * Untreated endodontic lesions, root fractures, extensive caries, or a hopeless prognosis involving the selected tooth. * Class II or III furcation involvement associated with the selected defect. * Known hypersensitivity to any material used in the study. * Inadequate oral hygiene or inability to meet the plaque-control requirements of the study protocol. * Current orthodontic treatment. * Inability or unwillingness to attend the scheduled follow-up visits.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Periodontal intrabony defects are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Gazi University Faculty of Dentistry, Department of Periodontology

    Ankara, Ankara, 06490, Turkey (Türkiye)

  • Çankırı Karatekin University Faculty of Dentistry, Department of Periodontology

    Çankırı, Çankırı, 18100, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.